8-K: Alpha Cognition Raises $35M in Oversubscribed Offering

Alpha Cognition Inc. successfully priced an oversubscribed public offering of common shares and pre-funded warrants, raising approximately $35 million to accelerate the commercial launch of ZUNVEYL.

Summary

• Alpha Cognition Inc. entered into an underwriting agreement with Titan Partners Group LLC for a public offering.
• The offering includes 4,651,516 common shares at $6.25 per share and pre-funded warrants to purchase up to 948,484 common shares at $6.249 per warrant, with an exercise price of $0.001 per share.
• The total number of common shares (or shares underlying pre-funded warrants) sold in the offering is 5,600,000.
• Gross proceeds from the offering are approximately $35.0 million, before deducting underwriting discounts and estimated offering expenses.
• The company expects its total cash position to be approximately $70 million following the closing of the offering.
• Net proceeds will be used for accelerating the commercial launch of ZUNVEYL, focusing on sales expansion, marketing investment, enhancing payer coverage, and reimbursement infrastructure.
• The underwriter has a 30-day option to purchase up to an additional 840,000 common shares to cover over-allotments.
• The offering was oversubscribed and received enthusiastic support from both existing and new healthcare investors.

Sentiment

Score: 8

Explanation: The successful pricing of an oversubscribed offering, coupled with strong investor support and a clear strategic use of proceeds for commercial launch, indicates a highly positive sentiment. The expected increase in cash position further strengthens the company's outlook.

Positives

• The public offering was oversubscribed, indicating strong investor confidence.
• Secured approximately $35.0 million in gross proceeds, significantly bolstering the company's financial position.
• Expected total cash position of approximately $70 million post-closing provides substantial capital for strategic initiatives.
• Funds are specifically allocated to accelerate the commercial launch of ZUNVEYL, a patented drug for Alzheimer's disease, which is a clear growth driver.
• The offering was led by an initial investment from a premier healthcare-dedicated investor, alongside multiple large existing shareholders, validating the company's vision and potential.

Negatives

• The offering involves the issuance of new common shares and pre-funded warrants, which will result in dilution for existing shareholders.

Risks

• Ability to raise sufficient capital to implement plans for commercializing ZUNVEYL.
• Efficacy and tolerability of ZUNVEYL.
• Ongoing regulatory oversight on the safety of ZUNVEYL.
• Market adoption of ZUNVEYL.
• Risks related to the company's intellectual property in relation to ZUNVEYL.
• Risks related to the commercial manufacturing, distribution, marketing, and sale of ZUNVEYL.
• Product liability risks.
• General risks described in the company's filings with the SEC, including those in its most recent Annual Report on Form 10-K and periodic reports on Form 10-Q and Form 8-K.

Future Outlook

The company intends to use the net proceeds from the offering to accelerate the commercial launch of ZUNVEYL, focusing on sales expansion, marketing investment, enhancing payer coverage, and reimbursement infrastructure. These investments are designed to maximize near-term adoption and establish a foundation for long-term revenue growth and a sustainable commercial presence in the Alzheimer's treatment landscape.

Management Comments

• "The enthusiastic support from both existing and new healthcare investors underscores confidence in our vision and growth potential."
• "We believe the net proceeds from this offering will accelerate the commercialization of ZUNVEYL (Benzgalantamine), enabling us to capitalize on early commercial learnings and set the foundation for key initiatives that will drive long-term shareholder value."

Industry Context

Alpha Cognition Inc. operates in the biopharmaceutical sector, specializing in treatments for neurodegenerative diseases, particularly Alzheimer's Disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The successful capital raise positions the company to advance the commercialization of its patented drug, ZUNVEYL, in the competitive Alzheimer's treatment market, where there are currently limited approved options for certain conditions. The focus on sales expansion, marketing, and payer coverage aligns with typical strategies for commercial-stage pharmaceutical companies launching new products.

Corporate Governance

Legal Proceedings

• No action, suit, inquiry, notice of violation, proceeding or investigation is pending or threatened against the company or its subsidiaries that would adversely affect the offering or result in a Material Adverse Effect.
• No investigation by the SEC involving the company or any current or former director or officer is pending or contemplated.
• The SEC has not issued any stop order suspending the effectiveness of any registration statement filed by the company.

Related Party Transactions

• No material transactions with officers, directors, or employees (or entities in which they have a substantial interest) exceeding $120,000, other than for standard compensation (salary, consulting fees, expense reimbursement, employee benefits including stock options), are disclosed beyond what is already in the General Disclosure Package.

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience dilution due to the issuance of new common shares and warrants, but the capital raise is intended to fund commercialization efforts that could drive long-term value. New investors gain exposure to the company's growth potential.
• **Employees:** The acceleration of commercial launch may lead to increased operational activities and potential job growth in sales, marketing, and support functions.
• **Customers/Patients:** The funding aims to enhance market adoption and accessibility of ZUNVEYL, potentially benefiting patients suffering from Alzheimer's disease.
• **Creditors:** The increased cash position strengthens the company's balance sheet, potentially improving its creditworthiness.
• **Management:** Lock-up agreements align management's interests with long-term shareholder value by restricting immediate sales of their holdings.

Next Steps

• The offering is expected to close on or about October 2, 2025, subject to customary closing conditions.
• The company will proceed with the acceleration of commercial launch for ZUNVEYL, focusing on sales expansion, marketing, payer coverage, and reimbursement infrastructure.
• The underwriter may exercise its 30-day option to purchase additional common shares.

Key Dates

Recommendation

The successful, oversubscribed public offering, raising $35 million, significantly strengthens Alpha Cognition's financial position, with an expected total cash of $70 million. This capital is strategically earmarked for accelerating the commercial launch of ZUNVEYL, a patented drug for Alzheimer's, which is a critical step towards revenue generation and market penetration. The enthusiastic support from premier healthcare investors validates the company's vision and growth potential. While dilution is a factor, the clear path to commercialization and robust funding for key initiatives in a high-need therapeutic area present a compelling 'buy' opportunity for long-term growth.

Keywords

Alpha Cognition, ACOG, Public Offering, Common Shares, Pre-Funded Warrants, Neurodegenerative Diseases, Alzheimer's Disease, ZUNVEYL, Biopharmaceutical, Commercial Launch, Capital Raise, SEC Filing, Underwriting Agreement, Healthcare Investment